Notícias

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

Mark Cuban on Monday urged investors to pressure major U.S. health insurers to address healthcare costs, calling on funds that hold shares in the industry to consider divesting their positions unless insurers change their practices. Shareholders in the Spotlight The...

UnitedHealth's operating margin has dropped well below its own long-run level, and by the company's own account the repair in its commercial business is a multi-year job rather than a finished one.

UnitedHealth Group has outpaced the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

Sen. Elizabeth Warren (D-Mass) has criticized the vertical integration in the U.S. healthcare system, arguing that it leads to higher costs for patients and increased profits for large corporations. Warren took to X on Sunday and used UnitedHealth Group Inc....

On July 29, UnitedHealth Group (NYSE:UNH) announced a $4 million commitment, funded through the United Health Foundation, to expand the University of Tennessee Health Sciences’ health hub network from 5 locations to 13 across the state by the end of 2027, a buildout expected to reach 200,000 Tennessee residents. It’s a modest sum for a […]

UnitedHealth Group (UNH) is back in focus after fresh attention on its Medicare Advantage and Optum Health businesses, which are helping offset pressure in commercial insurance and shaping how investors interpret the stock’s recent moves. See our latest analysis for UnitedHealth Group. Over the past year, UnitedHealth Group’s stock has combined a 21.01% year to date share price return with a 66.60% 1 year total shareholder return. The recent 1 month share price return of 4.13% and 7 day share...

In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.

Alignment Healthcare raises its 2026 outlook as membership and medical-cost trends improve, but heavier second-half investments could pressure near-term profitability.

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

Stock market leadership just flipped. The Nasdaq Composite rose 0.1% after opening lower. Driving the Nasdaq’s move was a sharp turnaround in chip stocks; the iShares Semiconductor ETF rallied 1.8% after opening sharply lower.

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

Chip stocks fell in Asia and the U.S. as investors once again grew nervous about the durability of artificial-intelligence spending, while oil held steady in early European trade.

UnitedHealth's revenue held up; the operating margin on it did not, and closing that gap is the whole upside case.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

South Korea's KOSPI swings highlight mounting AI stock volatility as investors brace for U.S. jobs data, Middle East tensions and India's rate decision.

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

UnitedHealth Group expanded its Tennessee health hub initiative in partnership with the University of Tennessee Health Sciences. The program is growing from 5 to 13 locations with a new $4 million commitment. The expansion focuses on preventive care, support for chronic conditions, and rural health resources across the state. UnitedHealth Group, listed as NYSE:UNH, is moving ahead with a larger on-the-ground health presence while its stock trades around $414.4. The company has a value score...

Janus Henderson Investors, an investment management company, released its “Forty Fund” Q2 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 19.00% in the second quarter of 2026, outperforming the Russell 1000 Growth Index’s 16.74% gain as strong stock selection and an overweight position in healthcare supported results. The […]

CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

The lever behind UnitedHealth stock's climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.

The average brokerage recommendation (ABR) for UnitedHealth (UNH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

These two stocks have been among the brighter spots for the company so far this year.

UnitedHealth Group has seen its analyst fair value estimate move from $424.23 to $475.23, a shift of about 12% in the underlying price target framework. Recent research attributes this change to Q2 earnings, updates around Medicare Advantage and Optum Health, and refreshed 2026 earnings models. These are cited as key reasons many analysts are resetting their targets higher while still flagging risks around commercial trends, Medicaid, and ongoing regulatory scrutiny. In the sections that...

The Centers for Medicare & Medicaid Services (CMS) announced Tuesday it will end the Medicare Part D Premium Stabilization Demonstration after the 2026 plan year, ending a federal subsidy program that has helped keep prescription drug premiums lower and could...

Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Vulcan Value Partners prioritizes long-term returns and lower risk over short-term performance. In the quarter, the Large Cap Composite (Net) returned 9.5%, the Small Cap Composite (Net) returned 13.3%, the Focus Composite (Net) returned 10.4%, the […]

Five Below delivered strong sales growth and raised guidance, while Whirlpool faced weakening demand and falling estimates as contrasting outlooks shaped the latest analysis.

Humana (NYSE:HUM) said its 2026 performance is tracking in line with expectations, with management emphasizing planned Medicare Advantage margin expansion in 2027, progress in its Stars program and continued operating-cost reductions as key components of its path toward a sustainable pretax margin o